These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21116282)

  • 1. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
    Quintás-Cardama A; Santos FP; Garcia-Manero G
    Leukemia; 2011 Feb; 25(2):226-35. PubMed ID: 21116282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
    Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
    Xu QY; Yu L
    Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
    Glasser CL; Lee A; Eslin D; Marks L; Modak S; Glade Bender JL
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):560-564. PubMed ID: 28562519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
    Voso MT; Lo-Coco F; Fianchi L
    Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
    Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
    Gore SD
    Leuk Res; 2009 Dec; 33 Suppl 2(Suppl 2):S2-6. PubMed ID: 20004793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
    Jabbour E; Garcia-Manero G
    Leuk Lymphoma; 2015 May; 56(5):1205-12. PubMed ID: 25058371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DAC system and associations with acute leukemias and myelodysplastic syndromes.
    Bug G; Ottmann OG
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S36-49. PubMed ID: 21153858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
    Bewersdorf JP; Shallis RM; Sharon E; Park S; Ramaswamy R; Roe CE; Irish JM; Caldwell A; Wei W; Yacoub A; Madanat YF; Zeidner JF; Altman JK; Odenike O; Yerrabothala S; Kovacsovics T; Podoltsev NA; Halene S; Little RF; Piekarz R; Gore SD; Kim TK; Zeidan AM
    Ann Hematol; 2024 Jan; 103(1):105-116. PubMed ID: 38036712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
    Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
    Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
    Cui Y; Cai J; Wang W; Wang S
    Front Immunol; 2021; 12():690207. PubMed ID: 34149732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.